{
    "output": [
        [
            "Rocket Pharmaceuticals, Ltd.",
            "ORG",
            "Merge",
            "Rocket Pharmaceuticals, Inc.",
            "ORG"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Operate_In",
            "New York City",
            "GPE"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Led_By",
            "Gaurav Shah",
            "PERSON"
        ],
        [
            "Gaurav Shah",
            "PERSON",
            "Role",
            "President and Chief Executive Officer",
            "TITLE"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Focus",
            "Gene Therapy Programs",
            "CONCEPT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Listed_On",
            "NASDAQ Global Market",
            "EXCHANGE"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Stock_Symbol",
            "RCKT",
            "TICKER"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Has",
            "Pipeline",
            "CONCEPT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Target",
            "Rare and Untreated Diseases",
            "CONCEPT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Lead_Program",
            "Phase 1/2 LVV-based gene therapy for Fanconi Anemia (FA)",
            "PRODUCT"
        ],
        [
            "Fanconi Anemia",
            "CONCEPT",
            "Causes",
            "Genetic Instability",
            "CONCEPT"
        ],
        [
            "Genetic Instability",
            "CONCEPT",
            "Due_To",
            "Mutations in DNA Repair Genes",
            "CONCEPT"
        ],
        [
            "Fanconi Anemia",
            "CONCEPT",
            "Results_In",
            "Early Bone Marrow Failure and Malignancy",
            "CONCEPT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Clinical_Trials",
            "Academic Partners in the U.S. and Europe",
            "ORG"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Expected",
            "Additional Patient Data in 2018",
            "EVENT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Anticipated",
            "Registration Study in 2019",
            "EVENT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "Three_Additional_Programs",
            "Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO)",
            "CONCEPT"
        ],
        [
            "Rocket Pharmaceuticals, Inc.",
            "ORG",
            "AAV-based_Gene_Therapy_Program",
            "Undisclosed Rare Pediatric Disease",
            "CONCEPT"
        ]
    ]
}